tbuckley/cabot-search huggingface dataset:
Errata
Journal: BMJ (1850)

demic diseases, and, finally, to peculiarities of constitution, which render many individuals absolutely insusceptible of being protected against a secondary attack, either by Vaccination or by inoculated or natural Small-pox.5. It has been proposed to re-introduce Variolous Inoculation as a certain remedy for the occasional failure of Vaccination,; but the superior efficacy of the practice is not only questionable, but its indis- criminate employment has been proved to be dangerous, and destructive of human life, and is therefore highly to be deprecated. 6. Revaccination, however, may be prudently recommnended, not only as innocuous in itself, but also, on various grounds, as positively advantageous, even by those who question the gradual extinction of the protective influence of Cow-pock.
Waterborne Cholera.
Authors: Ephraim Cutter
Journal: JAMA (1893)

New York, July 3, 1893. <h3>To the Editor:</h3> —The interested perusal of Dr. Ernest Hart's admirable paper which covers so much ground, prompts me to add a few words from Japan. The Hon. S. K. Takahash, late Consul General of Japan for the United States in 1886 said: "When we have cholera in Tokio, and our people die by the thousands, I notice that none in the Chinese quarter have cholera and that the Chinese<i>all drink boiled water</i>, to which this immunity is attributed." This strong, terse, positive and direct testimony it seems to me goes to sustain the positions of the distinguished gentlemen who has favored us so kindly with his extensive and timely observation. Respectfully yours,
Bupivacaine
Authors: Daniel C. Moore
Journal: JAMA (1970)

Bupivacaine (LAC 43, Marcaine [Sweden]) hydrochloride, a long-acting local anesthetic agent in concentrations of 0.1%, 0.25%, 0.5%, and 0.75% with and without a vasoconstrictor drug, was used in caudal, epidural, and peripheral nerve block. Onset occurred in 4 to 10 minutes and maximum analgesia in 15 to 30 minutes. Concentrations of 0.25%, 0.5%, and 0.75% consistently produced excellent sensory anesthesia, but only 0.75% consistently produced profound motor relaxation needed for intra-abdominal surgery. However, 0.25% and 0.5% were satisfactory in caudal, epidural, and peripheral nerve block for (1) pain relief of labor; (2) vaginal delivery; (3) perineal surgery; and (4) extremity surgery. Two inadvertent intravenous injections of 100 and 120 mg of bupivacaine hydrochloride caused mild systemic toxic reactions but no untoward sequelae. One inadvertent subarachnoid injection of 110 mg resulted in a total spinal block with an uneventful recovery.
The potential supply of organ donors. An assessment of the efficacy of organ procurement efforts in the United States
Authors: R. W. Evans
Journal: JAMA (1992)

<h3>Objectives.</h3> —To estimate the potential supply of organ donors and to measure the efficiency of organ procurement efforts in the United States. <h3>Methods.</h3> —A geographic database has been developed consisting of multiple cause of death and sociodemographic data compiled by the National Center for Health Statistics. All deaths are evaluated as to their potential for organ donation. Two classes of potential donors are identified: class 1 estimates are restricted to causes of death involving significant head trauma only, and class 2 estimates include class 1 estimates as well as deaths in which brain death was less probable. <h3>Results.</h3> —Over 23000 people are currently awaiting a kidney, heart, liver, heart-lung, pancreas, or lung transplantation. Donor supply is inadequate, and the number of donors remained unchanged at approximately 4000 annually for 1986 through 1989, with a modest 9.1% increase in 1990. Between 6900 and 10700 potential donors are available annually (eg, 28.5 to 43.7 per million population). Depending on the class of donor considered, organ procurement efforts are between 37% and 59% efficient. Efficiency greatly varies by state and organ procurement organization. <h3>Conclusions.</h3> —Many more organ donors are available than are being accessed through existing organ procurement efforts. Realistically, it may be possible to increase by 80% the number of donors available in the United States (up to 7300 annually). It is conceivable, although unlikely, that the supply of donor organs could achieve a level to meet demand. (<i>JAMA</i>. 1992;267:239-246)
Angiology, Baltimore
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PUVA APPRAISAL
Authors: E.M. Farber, E.A. Abel, H. Schaefer
Journal: British Journal of Dermatology (1978)

Journal Article PUVA APPRAISAL Get access E.M. Farber, E.M. Farber Stanford University Medical Center Stanford, California 94305, U.S.A. Search for other works by this author on: Oxford Academic Google Scholar E.A. Abel, E.A. Abel Stanford University Medical Center Stanford, California 94305, U.S.A. Search for other works by this author on: Oxford Academic Google Scholar H. Schaefer H. Schaefer Stanford University Medical Center Stanford, California 94305, U.S.A. Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 99, Issue 6, 1 December 1978, Pages 715–717, https://doi.org/10.1111/j.1365-2133.1978.tb07068.x Published: 01 December 1978
Use of coronary artery bypass surgery in the United States and Canada. Influence of age and income
Authors: G. M. Anderson
Journal: JAMA (1993)

<h3>Objective.</h3> —To compare overall rates of coronary artery bypass surgery (CABS) in several Canadian and US jurisdictions and to compare use by age and income groups in the two countries. <h3>Design.</h3> —Survey, using computerized hospital discharge abstracts. <h3>Setting.</h3> —All nonfederal hospitals in New York, California, Ontario, Manitoba, and British Columbia between 1983 and 1989. <h3>Patients.</h3> —All adult residents of the five jurisdictions who underwent CABS in a hospital in their jurisdiction. <h3>Results.</h3> —Between 1983 and 1989, the CABS rates were consistently highest in California and lowest in the Canadian jurisdictions. In 1989, the age-adjusted rate of CABS in California (112.5/100 000 adults) was 27% higher than in New York (88.4/100 000) and 80% higher than in the three Canadian provinces combined (62.4/100 000). The CABS rates increased for those aged 65 years and older and decreased for those aged 20 to 54 years in all five jurisdictions. In 1989, CABS rates were three times higher in California than in Canada for those aged 75 years and older, and the higher rates for those aged 65 years and older accounted for 75% of the overall difference in rates between California and Canada. In Canada, CABS rates for the nonelderly varied little by income of area of residence, but in New York and California, rates increased steadily with the income of area of residence. <h3>Conclusion.</h3> —Control over the supply of resources in Canada is associated with markedly lower CABS rates for the elderly than found in the United States. While overall rates are lower in Canada, the Canadian universal health insurance system reduces the influence of income on access to CABS found in the United States. However, even without universal health insurance, CABS rates for the nonelderly living in the poorest areas in California are similar to the rates for those living in the poorest parts of Canada. (<i>JAMA</i>. 1993;269:1661-1666)
ORIGINAL ARTICLES.
Journal: JAMA (1889)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cell Cycle Controls: Potential Targets for Chemical Carcinogens?
Authors: Cynthia A. Afshari, J. Carl Barrett
Journal: Environmental Health Perspectives (1993)

The progression of the cell cycle is controlled by the action of both positive and negative growth regulators.The key players in this activity include a family of cyclins and cyclin-dependent kinases, which are themselves regulated by other kinases and phosphatases.Maintenance of balanced cell cycle controls may be directly linked to genomic stability.Loss of the check- points involved in cell cycle control may result in unrepaired DNA damage during DNA synthesis or mitosis leading to genetic mutations and contributing to carcinogenesis.
Clinical Lectures ON THE BORDERLAND OF EPILEPSY: VERTIGO: Delivered at the National Hospital for the Paralysed and Epileptic
Authors: W. R. Gowers
Journal: BMJ (1906)

GENTLEMEN,-In tlle last lecture we considered the features of aural vertigo which resemble the symptoms of epileptic seizures-suddeniness, brevity, loss of conscious- iiess, loss of sight, and also the remarkable sense of impulsion downwards by an externial force, sometimes so intense as to amount to a feeling that a blow has been received.The latter, although suggestive of an epileptic sensation, is probably peculiar to vertigo.Other cephalic sensations, various in character, may attend the onset of the attack.Sometimes they are allied to that which we have just considered.A lady of 27, with the remains of otitis media on the right side, ancd some labyrinthine deafness on the left, had also constant tinnitus, continuous, at times louder, aild then pulsating like an engine.Her attacks of giddiness began with a sudden sensation in one side of the head, which seemed as if it would throw her down.But the sensation varied, and sometimes was beating" in character-half sound and half pressure- which made her hold her head firmly with her hands.Oceasionally Elhe woke up in the niight with a loud noise like machinery in the right ear, and this seemed to pass gradually to the middle of the head and then to the left side; it lasted longsometimes eveli twenty-four hours- and while it conitiniued she could hear nothinig.Of special interest is the fact that the senlse of pressure seemed also to cause impulsion.These cephalic sensation-s, at the onset of an attack of vertigo, are sometimes very mis- leading.They are so obtrusive as to absorb the attention of the patient.In onle inistance of this, the aural origin of the symptoms rested on the tinniiitus, since hearinig was grood-at least for a lady of 60.For maniy months she lhad been troubled by a loud noise, referred to both ears, compared to the sound of a steam-engine at work.During the last three months there had been ver- tigo, moderate, often lasting sever al liours at a time,
Leukotoxin and its diol induce neutrophil chemotaxis through signal transduction different from that of fMLP
Authors: Y. Totani, Y. Saito, T. Ishizaki, F. Sasaki, S. Ameshima, I. Miyamori
Journal: European Respiratory Journal (2000)

When injected into animals, leukotoxin (Lx) causes acute lung injury which is associated with neutrophils infiltrating the lung tissues. However, the effect of Lx on neutrophils is still unknown, and recently it has been reported that Lx diol, a hydrolyzed metabolite, should be more potent than Lx in vitro. In this study, the authors examined the effect of Lx and its diol on human neutrophils by assessing their chemotactic response, expression of adhesion molecules, and production of peroxides. Both Lx and its diol induced chemotaxis in human neutrophils via an involvement of pertussis toxin-sensitive G-proteins, but they did not influence the expression of adhesion molecules or the production of peroxides. Furthermore, Lx synergistically affected chemotaxis with N-formyl-methionyl-leucyl-phenylalanine (fMLP), but not with endothelin-1. Neutrophil chemotaxis induced by both Lx and its diol was inhibited by phosphatidylinositol-3-kinase (PI3-K) inhibitors, but not by protein tyrosine kinase (PTK) inhibitors or by protein kinase C (PKC) inhibitors, whereas fMLP-induced chemotaxis was inhibited by PTK inhibitors, but not by PI3-K inhibitors or by PKC inhibitors. These results suggest that neutrophil chemotaxis induced by both Lx and its diol involves pathways different from those induced by fMLP. In conclusion, both leukotoxin and its diol metabolite induce chemotaxis in human neutrophils in a unique way and may act as important bioactive lipids when considering the pathological mechanism of acute lung injury.
Neck injury to women in auto accidents. A metropolitan plague
Authors: C. H. Schutt
Journal: JAMA (1968)

Disabling neck injuries to women in auto accidents are common in metropolitan regions, 6.7/1,000 women year. Near Newark, NJ, the rate was 14.5/1,000/year, half occurring from rear-end collisions. Absence from work averaged eight weeks. Delayed onset was not associated with longer absence. Symptoms continued more than six months in about 75% of those without, as well as with pending litigation. These and other data do not support the opinion that prolonged symptoms are commonly due to litigation neurosis or malingering. Reports of electroencephalographic abnormalities in a high proportion of humans and animals with whiplash injury plus damage to the sympathetic and cerebrospinal nervous systems and rupture of stabilizing ligaments indicate possible organic bases for "neurosis." Proper headrests prevent whiplash injury to humans. Federal regulations require headrests in automobiles made after Dec 31, 1968.
Abstract 1363: Development of novel anticancer agents based on fusarochromanone
Authors: Elahe Mahdavian, Dakota Boston, Reid Grimes, Tara Williams-Hart, Brian Furmanski, John Clifford, Brian Salvatore
Journal: Cancer Research (2011)

Abstract The primary goal of this research is to develop novel anti-cancer agents based on fusarochromanone (FC101a), a natural mycotoxin with potent anti-angiogenic and direct anti-tumor activity. This research may lead to new cancer chemotherapeutic agents that are more potent and less toxic than conventional chemotherapy. Like most other bioactive natural compounds, the potency of FC101a is compromised in-vivo, suggesting unfavorable bioavailability, distribution, and/or metabolism. Development of FC101a as a chemotherapeutic drug requires the completion of its total synthesis, as well as the synthesis of a series of structural analogs with greater in-vivo potency than the lead compound. Progress towards both the chemical and biological synthesis of FC101a will be presented. We have employed a new pathway for synthesizing the unique multifunctional four-carbon side chain in the parent compound. We have also been successful in synthesizing the 6-iodo-4-chromanone, a key intermediate that is needed for the coupling reaction with the side-chain. Additionally, we have synthesized two novel acetal analogs of FC101a and will present the rational for choosing these structural analogs for devising structure activity relationships for this series of compounds. For the biological synthesis, we have obtained a highly fluorescent metabolite from the rice culture of two Fusarium strains (#4482 and #8508) that resembles FC101a, based on TLC analyses. We have also developed an efficient HPLC purification protocol to obtain samples of this compound with high purity. We are currently working to scale up this separation and confirm the structure of this compound through 1H, 13C-NMR as well as high-resolution mass spectrometry analyses. We will report our preliminary results on the inhibition effects of FC101a on the growth of human aggressive skin cancer carcinoma (SCC) both in-vitro and in-vivo. We have also investigated the mechanism of the biological function of FC101a. We will report our results on the expression levels and phosphorylation states of key proteins involved in cell proliferation signaling pathways, cell sorting profiles, and FACS analyses. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1363. doi:10.1158/1538-7445.AM2011-1363
Simulated abuse of tybamate in man. Failure to demonstrate withdrawal reactions
Authors: J. Shelton
Journal: JAMA (1967)

TYBAMATE is a chemical analogue of meprobamate which shares many of the pharmacological properties of the latter drug (Figure). These properties include sedative, anticonvulsant, and musclerelaxant effects. Tybamate differs from meprobamate in that it reverses the electroencephalographic activation produced by lysergic acid diethylamide tartrate (LSD-25) in rabbits, antagonizes the rise in blood pressure induced by serotonin in dogs, and is extensively bound to protein.<sup>1</sup>A number of clinical reports, including some double-blind comparisons with placebo and meprobamate, attest to its clinical efficacy.<sup>2,3</sup>Despite considerable clinical use, so far no instances of withdrawal reactions have been encountered. Early investigations suggested freedom from withdrawal effects. Even when administered over a long period of time to dogs in doses of 570 mg/kg of body weight; no withdrawal seizures were encountered; dogs treated with comparable doses of meprobamate had frequent withdrawal seizures, often fatal.<sup>4</sup> As canine withdrawal reactions have correlated well
The state of the art
Authors: A. R. Feinstein
Journal: JAMA (1986)

Her chief complaint is that she wants to die and that the doctors will not let her. She is 96 years old. She has attended the burial of her husband, two daughters-in-law, and all the people who were close friends throughout her lifetime. A woman of fierce and independent spirit, she never wanted to live with her children, to be supported by them, or to be what she calls "a burden." After being widowed 24 years ago, she achieved those goals for a long time because she was in good health and her modest fiscal needs were met by the interest of the trust fund left by her husband. Until 11 years ago, she lived alone and maintained her own apartment. She spent her time walking, talking with neighbors, reading, watching television, playing card games, attending religious services, and traveling to visit children, grandchildren, and great-grandchildren in different cities. At
NECROLOGY.
Journal: JAMA (1894)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Rethinking Drinking
Authors: Bridget M. Kuehn
Journal: JAMA (2009)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Book Review
Authors: N. BREEN
Journal: JNCI Journal of the National Cancer Institute (1993)

Book Review Get access Who Survives Cancer? Howard P. Greenwald . Berkeley, Calif. : Univ. Calif. Press , 1992 . 280 pp., illus. $25. ISBN 0-520-07725-3 NANCY BREEN, Ph.D. NANCY BREEN, Ph.D. Applied Research Branch, Division of Cancer Prevention and Control, National Cancer Institute, National Institutes of HealthExecutive Plaza North, Suite 313 6130 Executive Blvd. Rockville, MD 20852 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 85, Issue 24, December 1993, Pages 2034–2035, https://doi.org/10.1093/jnci/85.24.2034 Published: 01 December 1993